Insider Selling: TherapeuticsMD Inc (TXMD) Insider Sells 129,000 Shares of Stock

TherapeuticsMD Inc (NASDAQ:TXMD) insider John C.K. Iv Milligan sold 129,000 shares of the stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $4.98, for a total transaction of $642,420.00. Following the transaction, the insider now owns 1,601,419 shares in the company, valued at $7,975,066.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

John C.K. Iv Milligan also recently made the following trade(s):

  • On Thursday, December 6th, John C.K. Iv Milligan sold 258,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.77, for a total transaction of $1,230,660.00.
  • On Thursday, November 29th, John C.K. Iv Milligan sold 258,128 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.96, for a total transaction of $1,280,314.88.
  • On Thursday, November 15th, John C.K. Iv Milligan sold 258,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.90, for a total transaction of $1,264,200.00.
  • On Wednesday, October 24th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.35, for a total transaction of $1,337,500.00.
  • On Wednesday, October 10th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.85, for a total transaction of $1,462,500.00.
  • On Wednesday, September 26th, John C.K. Iv Milligan sold 125,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.78, for a total transaction of $847,500.00.
  • On Tuesday, September 11th, John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.10, for a total transaction of $1,525,000.00.

NASDAQ:TXMD traded down $0.22 during midday trading on Thursday, reaching $4.63. 4,088,475 shares of the stock traded hands, compared to its average volume of 2,618,062. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.51 and a beta of 1.35. TherapeuticsMD Inc has a 12-month low of $4.30 and a 12-month high of $7.66. The company has a quick ratio of 7.15, a current ratio of 7.23 and a debt-to-equity ratio of 0.55.



TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Wednesday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.06. The business had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $4.43 million. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The business’s quarterly revenue was down 21.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.07) earnings per share. As a group, analysts expect that TherapeuticsMD Inc will post -0.58 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of TherapeuticsMD by 10.6% in the third quarter. BlackRock Inc. now owns 16,070,569 shares of the company’s stock worth $105,421,000 after buying an additional 1,537,045 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of TherapeuticsMD by 9.8% in the third quarter. Vanguard Group Inc. now owns 12,894,027 shares of the company’s stock worth $84,585,000 after buying an additional 1,153,716 shares during the last quarter. FMR LLC raised its holdings in shares of TherapeuticsMD by 14.7% during the third quarter. FMR LLC now owns 12,049,988 shares of the company’s stock worth $79,048,000 after purchasing an additional 1,542,987 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of TherapeuticsMD by 7.7% during the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock worth $21,336,000 after purchasing an additional 242,995 shares during the last quarter. Finally, First Eagle Investment Management LLC raised its holdings in shares of TherapeuticsMD by 26.9% during the third quarter. First Eagle Investment Management LLC now owns 2,864,565 shares of the company’s stock worth $18,792,000 after purchasing an additional 606,813 shares during the last quarter. 72.66% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of TherapeuticsMD in a research report on Friday, November 23rd. BidaskClub raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, November 23rd. Oppenheimer set a $14.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, November 7th. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, November 2nd. Finally, ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Monday, October 29th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $13.45.

COPYRIGHT VIOLATION WARNING: This story was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://dakotafinancialnews.com/2018/12/07/insider-selling-therapeuticsmd-inc-txmd-insider-sells-129000-shares-of-stock.html.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Further Reading: What is a conference call?

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply